drugset
drugset / Trial / NCT05312879

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

NCT05312879 ↗

Phase 2/3 Recruiting 466 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Timeline

Start
2022-03-30
Primary completion
2028-06-02
Completion
2030-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Inaxaplin Small molecule — Oral

Indications

proteinuria